Würzburg researchers have discovered a novel approach to preventing thrombosis, offering a fresh perspective on the role of GPVI receptors in blood clotting and vascular health. This groundbreaking study, published in the journal Signal Transduction and Targeted Therapy, introduces a unique platelet phenotype, dubbed GPVILO, which holds significant promise for safer antithrombotic therapies.
A Receptor's Dual Role
Glycoprotein VI (GPVI) is a crucial player in hemostasis, the body's natural process of stopping bleeding. It binds to collagen at injured blood vessel sites, triggering platelet activation and aggregation. However, excessive GPVI activation can lead to pathological thrombi formation, causing vascular occlusions and potentially life-threatening events like heart attacks and strokes.
Prof. Dr. Bernhard Nieswandt, a renowned expert in the field, first described GPVI's function in 2001. His research has paved the way for the development of GPVI inhibitors, with EMA601, a GPVI-blocking antibody, recently entering preclinical trials with Boehringer Ingelheim and EMFRET Analytics. Nieswandt's team demonstrated EMA601's effectiveness in preventing thrombosis without compromising vital blood clotting.
Beyond Inhibition: Controlling Receptor Density
The latest study takes a different approach by focusing on receptor density rather than complete inhibition. Researchers found that reducing GPVI density on platelets, achieved through antibodies with low binding strength (JAQ1 antibodies), resulted in a stable "GPVI-low" phenotype (GPVILO).
Dr. Stefano Navarro, the first author, highlights the surprising discovery that partial receptor loss doesn't simply lead to an intermediate state. Instead, it creates a distinct platelet phenotype, GPVILO, which maintains hemostatic function while exhibiting strong antithrombotic efficacy.
GPVILO: A New Platelet State
Surprisingly, GPVILO platelets retained their ability to adhere to injured blood vessels and stop bleeding, even when combined with high-dose aspirin. This contrasts with complete GPVI depletion, which can impair hemostasis. The study reveals that GPVILO platelets significantly reduce signals contributing to blood clot formation and stabilisation, offering a delicate balance between hemostasis and thrombosis prevention.
Therapeutic Implications
This novel approach opens up exciting possibilities for safer antithrombotic therapies. Instead of completely blocking GPVI, controlling receptor density could become a therapeutic principle. GPVILO platelets demonstrated reliable protection against arterial thrombosis and inflammatory lung injury in experimental models, suggesting a potential for treating various disease states.
Nieswandt emphasises the broader implications, suggesting that long-term anti-GPVI therapy could go beyond thrombosis prevention. It might contribute to treating inflammatory diseases like ischemic stroke, acute lung injury, and potentially cancer metastases, marking a significant advancement in our understanding of GPVI's role in health and disease.
